| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000411136 |
| ISSN: | 1665-2681 |
| Autores: | Gana, Juan Cristóbal1 Serrano, Carolina A1 Ling, Simon C2 |
| Instituciones: | 1Pontificia Universidad Católica de Chile, Escuela de Medicina, Santiago de Chile. Chile 2University of Toronto, Toronto, Ontario. Canadá |
| Año: | 2016 |
| Periodo: | May-Jun |
| Volumen: | 15 |
| Número: | 3 |
| Paginación: | 303-313 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico |
| Resumen en inglés | In patients with advanced liver disease with portal hypertension, portal-systemic collaterals contribute to circulatory disturbance, gastrointestinal hemorrhage, hepatic encephalopathy, ascites, hepatopulmonary syndrome and portopulmonary hypertension. Angiogenesis has a pivotal role in the formation of portal-systemic shunts. Recent research has defined many of the mediators and mechanisms involved in this angiogenic process, linking the central roles of hepatic stellate cells and endothelial cells. Studies of animal models have demonstrated the potential therapeutic impact of drugs to inhibit angiogenesis in cirrhosis. For example, inhibition of VEGF reduces portal pressure, hyperdynamic splanchnic circulation, portosystemic collateralization and liver fibrosis. An improved understanding of the role of other angiogenic factors provides hope for a novel targeted therapy for portal hypertension with a tolerable adverse effect profile |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Sistema cardiovascular, Angiogénesis, Patogénesis, Hipertensión portal, Fibrosis hepática |
| Keyword: | Medicine, Cardiovascular system, Gastroenterology, Angiogenesis, Pathogenesis, Portal hypertension, Liver fibrosis |
| Texto completo: | Texto completo (Ver PDF) |
